Bicocca Open Archive

Logo unimib boa
FONTANA, DILETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.166
AS - Asia 4.758
EU - Europa 3.817
SA - Sud America 756
AF - Africa 125
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 7
Totale 15.659
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.881
SG - Singapore 1.493
IT - Italia 1.236
CN - Cina 957
VN - Vietnam 927
DE - Germania 632
HK - Hong Kong 561
BR - Brasile 558
RU - Federazione Russa 516
IE - Irlanda 277
SE - Svezia 264
CA - Canada 207
GB - Regno Unito 189
FR - Francia 176
IN - India 136
FI - Finlandia 100
KR - Corea 100
ID - Indonesia 98
BD - Bangladesh 96
AR - Argentina 79
IQ - Iraq 78
UA - Ucraina 74
ES - Italia 73
TR - Turchia 73
PL - Polonia 54
JP - Giappone 47
MX - Messico 43
AT - Austria 41
NL - Olanda 41
ZA - Sudafrica 41
CH - Svizzera 39
PK - Pakistan 35
EC - Ecuador 29
SA - Arabia Saudita 25
BE - Belgio 22
PH - Filippine 22
AU - Australia 21
DK - Danimarca 21
UZ - Uzbekistan 21
VE - Venezuela 21
PE - Perù 20
CO - Colombia 18
MA - Marocco 18
CZ - Repubblica Ceca 17
EG - Egitto 13
LT - Lituania 13
IR - Iran 12
TN - Tunisia 11
KE - Kenya 10
UY - Uruguay 10
CL - Cile 9
ET - Etiopia 9
PY - Paraguay 9
AZ - Azerbaigian 8
NI - Nicaragua 7
NP - Nepal 7
NZ - Nuova Zelanda 7
DO - Repubblica Dominicana 6
JO - Giordania 6
KG - Kirghizistan 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
EU - Europa 5
NO - Norvegia 5
CR - Costa Rica 4
DZ - Algeria 4
IL - Israele 4
LY - Libia 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
RO - Romania 4
AL - Albania 3
AM - Armenia 3
BG - Bulgaria 3
BM - Bermuda 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
GR - Grecia 3
HN - Honduras 3
KZ - Kazakistan 3
MU - Mauritius 3
PT - Portogallo 3
TH - Thailandia 3
CY - Cipro 2
GT - Guatemala 2
HU - Ungheria 2
JM - Giamaica 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MM - Myanmar 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
Totale 15.639
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.055
Singapore 841
Ashburn 628
San Jose 574
Hong Kong 534
Milan 442
Frankfurt am Main 413
Ho Chi Minh City 290
Dublin 274
Hanoi 227
Chandler 224
Dallas 207
Los Angeles 203
Wilmington 172
New York 168
Fairfield 167
Beijing 156
Hefei 152
Houston 138
Toronto 137
Santa Clara 119
The Dalles 109
Chicago 99
Dearborn 91
Seoul 90
Munich 84
Woodbridge 84
Jakarta 71
Seattle 69
São Paulo 66
Shanghai 63
Boardman 58
Lauterbourg 56
Princeton 56
Helsinki 53
Buffalo 51
Moscow 46
Cambridge 45
Council Bluffs 44
Da Nang 42
Jacksonville 41
Orem 38
Warsaw 37
Kent 36
Nuremberg 33
Boyds 31
Altamura 30
Zurich 30
Guangzhou 29
London 29
Nanjing 29
Tokyo 29
Haiphong 28
Johannesburg 28
Lawrence 26
Montreal 26
Chennai 25
Kirkuk 25
Baghdad 24
Biên Hòa 23
Turku 23
Vienna 23
Hải Dương 22
Monza 22
Poplar 22
Atlanta 21
Dong Ket 21
Sesto San Giovanni 20
Stockholm 20
Denver 19
Washington 19
Desio 18
Rio de Janeiro 18
Rome 18
Romola 18
Tashkent 18
Phoenix 17
Brussels 16
Tianjin 16
Turin 16
Amsterdam 15
Ha Long 15
Kocaeli 15
Lima 15
Pavia 15
Belo Horizonte 14
Carate Brianza 14
Genoa 14
Istanbul 14
Paris 14
San Diego 14
Ankara 13
Boston 13
Lappeenranta 13
Salt Lake City 13
Lissone 12
Meda 12
Ottawa 12
Pune 12
Riyadh 12
Totale 9.653
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 606
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 466
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 455
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 454
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 450
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 448
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 437
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 421
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 412
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 382
Idiopathic erythrocytosis: a germline disease? 378
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 378
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 375
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 371
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 370
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 345
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 344
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 327
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 321
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 307
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 305
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 301
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 287
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 287
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 285
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 274
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 270
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 262
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 260
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 259
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 258
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 254
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 243
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 238
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 238
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 229
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 220
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 218
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 217
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 215
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 211
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 196
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 194
Role of somatic ETNK1 mutation in the mitochondrial activity 191
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 191
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 188
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape 186
Integrating mutational profiles and single-cell transcriptional data using LASSO regularized regression to elucidate key molecular functions involved in the pathogenesis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia 185
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 184
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 179
ETNK1 mutations increase mitochondrial activity and promote DNA damage through ROS production 167
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia 161
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 156
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 152
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 145
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 125
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer 104
Totale 16.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.171
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.171
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021111 0 0 0 0 0 0 0 0 0 0 0 111
2021/2022651 84 88 79 61 36 59 21 20 30 43 56 74
2022/20231.152 108 271 124 104 110 152 18 62 64 34 32 73
2023/20241.216 46 43 64 76 122 276 235 36 105 52 51 110
2024/20253.188 149 284 170 172 254 120 222 114 334 576 285 508
2025/20267.365 1.169 544 612 880 704 342 1.118 299 514 671 352 160
Totale 16.082